These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36752506)

  • 41. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Derman BA; Streck M; Wynne J; Christ TN; Curran E; Stock W; Knoebel RW
    Leuk Lymphoma; 2020 Mar; 61(3):614-622. PubMed ID: 31680584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity and toxicity of intramuscular 1000 iu/m
    Sidhu J; Masurekar AN; Gogoi MP; Fong C; Ioannou T; Lodhi T; Parker C; Liu J; Kirkwood AA; Moorman AV; Das K; Goulden NJ; Vora A; Saha V; Krishnan S
    Br J Haematol; 2022 Jul; 198(1):142-150. PubMed ID: 35348200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
    Dunn KA; Connors J; Bielawski JP; Nearing JT; Langille MGI; Van Limbergen J; Fernandez CV; MacDonald T; Kulkarni K
    Leuk Lymphoma; 2021 Apr; 62(4):927-936. PubMed ID: 33258724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis.
    Mauney EE; Power-Hays A; Flamand Y; Vrooman L; Silverman LB; Grover AS
    J Pediatr Gastroenterol Nutr; 2022 Mar; 74(3):402-407. PubMed ID: 34694268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia.
    Sahu S; Saika S; Pai SK; Advani SH
    Pediatr Hematol Oncol; 1998; 15(6):533-8. PubMed ID: 9842647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
    Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
    Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?
    Lashkari HP; Lancaster D; Atra A; Champion MP; Taj MM
    Int J Hematol; 2011 Dec; 94(6):571-5. PubMed ID: 22057510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels.
    Minowa K; Suzuki M; Fujimura J; Saito M; Koh K; Kikuchi A; Hanada R; Shimizu T
    Drugs R D; 2012 Jun; 12(2):49-55. PubMed ID: 22594522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
    Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase].
    Wlazłowski M; Celińska W; Maciejka-Kapuścińska L; Płoszyńska A; Idczak E
    Pol Tyg Lek; 1994 Mar 21-28; 49(12-13):296-7. PubMed ID: 7808958
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
    Alrazzak M; Beaupin LK; Kinyoun P; Barth M
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach.
    Siebel C; Lanvers-Kaminsky C; Alten J; Smisek P; Nath CE; Rizzari C; Boos J; Würthwein G
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):187-198. PubMed ID: 34878584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study.
    Lynggaard LS; Rank CU; Hansen SN; Gottschalk Højfeldt S; Henriksen LT; Jarvis KB; Ranta S; Niinimäki R; Harila-Saari A; Wolthers BO; Frandsen TL; Heyman M; Schmiegelow K; Albertsen BK
    Blood Adv; 2022 Jan; 6(1):138-147. PubMed ID: 34625787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.